Clinical Trials Directory

A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use

BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating patients who have recurrent or refractory advanced T-cell leukemia. Patients will receive an infusion of BCX-1777 on days 1-5. Treatment may be repeated every week for up to six courses. Patients are not required to be hospitalized for the administration of BCX-1777. Some patients may continue to receive an infusion of BCX-1777 twice a week for 6 weeks.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : forodesine hydrochloride (BCX-1777)

Phase: Phase 2


Ages Eligible For Study:

N/A - N/A

Inclusion Criteria

- Documented T-cell leukemia (precursor T-lymphoblastic leukemia/lymphomia or T-PLL) - Failure to have responded to one or more standard regimens for their disease. - Performance status of <=2 by Eastern Cooperative Oncology Group (ECOG) criteria - All ages are eligible - Life expectancy of at least 3 months - Adequate liver function (aspartate transaminase [AST] and/or alanine transaminase [ALT] not >3 times upper limits or normal [ULN]) - Adequate kidney function (calculated creatinine clearance >50 mL/min) - Negative urine pregnancy test within 2 to 7 days prior to the start of study treamtment in females of childbearing potential - Females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study - Signed informed consent/assent form (ICF) prior to start of any study specific procedures

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Nadeem Mukhtar
Not Recruiting

Footer Links: